Cite
Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells.
MLA
Lazzerini, Lea, et al. “Favorable Therapeutic Response after Anti-Mesothelin Antibody–drug Conjugate Treatment Requires High Expression of Mesothelin in Tumor Cells.” Archives of Gynecology & Obstetrics, vol. 302, no. 5, Nov. 2020, pp. 1255–62. EBSCOhost, https://doi.org/10.1007/s00404-020-05734-9.
APA
Lazzerini, L., Jöhrens, K., Sehouli, J., & Cichon, G. (2020). Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells. Archives of Gynecology & Obstetrics, 302(5), 1255–1262. https://doi.org/10.1007/s00404-020-05734-9
Chicago
Lazzerini, Lea, Korinna Jöhrens, Jalid Sehouli, and Günter Cichon. 2020. “Favorable Therapeutic Response after Anti-Mesothelin Antibody–drug Conjugate Treatment Requires High Expression of Mesothelin in Tumor Cells.” Archives of Gynecology & Obstetrics 302 (5): 1255–62. doi:10.1007/s00404-020-05734-9.